Hypertrophic Scar clinical trials at UCSF

1 research study open to eligible people

A hypertrophic scar is a thickened, raised area of skin that forms after an injury. UCSF is studying a tissue bridge device to see if it can prevent these scars after gender-affirming mastectomy. This clinical trial involves testing the device in a controlled and random manner.

Showing trials for

  • Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affirming Mastectomy

    open to eligible people ages 19 years and up

    The goal of this randomized, prospective, interventional clinical trial is to evaluate the use of Brijjit® in reducing the incidence of hypertrophic scarring in individuals undergoing gender-affirming bilateral double incision mastectomies at a single-institution, single-surgeon site (Esther A. Kim, MD). Patients will serve as a self-control (one side of the chest receives intervention, the other serves as a control). Primary endpoints include scar appearance and quality. Secondary endpoints include patient perception of the scar using the Patient and Observer Scar Assessment Scale (POSAS). Participants will be taught how to apply Brijjit® at home if any units fall off before 6 weeks postop.

    San Francisco, California

Our lead scientists for Hypertrophic Scar research studies include .

Last updated: